Lista de obras - Marjorie Zauderer - Dominio Público Uruguay

"A Tool, Not a Crutch": Patient Perspectives About IBM Watson for Oncology Trained by Memorial Sloan Kettering

artículo científico publicado en 2019

A Randomized Phase II Trial of Adjuvant Galinpepimut-S, WT-1 Analogue Peptide Vaccine, After Multimodality Therapy for Patients with Malignant Pleural Mesothelioma

artículo científico publicado en 2017

A new standard for malignant pleural mesothelioma

artículo científico publicado en 2015

A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma

scientific article published on 07 May 2019

A prospective study of tumor suppressor gene methylation as a prognostic biomarker in surgically resected stage I to IIIA non-small-cell lung cancers.

artículo científico publicado en 2014

COVID-19 in patients with lung cancer

scientific article published on 16 June 2020

Cancer antigen profiling for malignant pleural mesothelioma immunotherapy: expression and coexpression of mesothelin, cancer antigen 125, and Wilms tumor 1.

artículo científico publicado en 2017

Change in cycle 1 to cycle 2 haematological counts predicts toxicity in older patients with breast cancer receiving adjuvant chemotherapy

artículo científico publicado en 2005

Chemotherapy-induced immunomodulation in non-small-cell lung cancer: a rationale for combination chemoimmunotherapy

artículo científico publicado en 2017

Clinical characteristics of patients with malignant pleural mesothelioma harboring somatic BAP1 mutations.

artículo científico publicado en 2013

Combined Inhibition of NEDD8-Activating Enzyme and mTOR Suppresses NF2 Loss-Driven Tumorigenesis.

artículo científico publicado en 2017

Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization

scientific article published on 31 May 2016

Contemporary Analysis of Prognostic Factors in Patients with Unresectable Malignant Pleural Mesothelioma

artículo científico publicado en 2015

Creating a Synthetic Clinical Trial: Comparative Effectiveness Analyses Using an Electronic Medical Record

artículo científico publicado en 2019

Current and Future Management of Malignant Mesothelioma : A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer and Mesothelioma Applied Research Foundatio

artículo científico publicado en 2018

Developing a cancer-specific geriatric assessment

artículo científico publicado en 2005

Failure patterns after hemithoracic pleural intensity modulated radiation therapy for malignant pleural mesothelioma

artículo científico publicado en 2014

Feasibility and toxicity of dose-dense adjuvant chemotherapy in older women with breast cancer

artículo científico publicado en 2008

Globular C1q Receptor (gC1qR/p32/HABP1) Is Overexpressed in Malignant Pleural Mesothelioma and Is Associated With Increased Survival in Surgical Patients Treated With Chemotherapy

artículo científico publicado en 2019

Heart Dosimetry is Correlated With Risk of Radiation Pneumonitis After Lung-Sparing Hemithoracic Pleural Intensity Modulated Radiation Therapy for Malignant Pleural Mesothelioma

artículo científico

Hemithoracic radiotherapy for mesothelioma: lack of benefit or lack of statistical power?

artículo científico publicado en 2016

Important recent insights into the genetics and biology of malignant pleural mesothelioma

artículo científico publicado en 2012

Improved Outcomes with Modern Lung-Sparing Trimodality Therapy in Patients with Malignant Pleural Mesothelioma.

artículo científico publicado en 2017

Inherited Rare, Deleterious Variants in ATM Increase Lung Adenocarcinoma Risk

artículo científico publicado en 2020

Integrative Molecular Characterization of Malignant Pleural Mesothelioma

artículo científico publicado en 2018

Leptomeningeal metastases from small cell lung cancer responsive to temozolomide therapy

artículo científico publicado en 2010

Localized malignant pleural mesothelioma with renal metastasis

artículo científico publicado en 2015

Loss of BAP1 as a candidate predictive biomarker for immunotherapy of mesothelioma

Malignant Pleural Mesothelioma: Are There Imaging Characteristics Associated With Different Histologic Subtypes on Computed Tomography?

artículo científico publicado en 2018

Mesothelioma: Scientific clues for prevention, diagnosis, and therapy

artículo científico publicado en 2019

New strategies in pleural mesothelioma: BAP1 and NF2 as novel targets for therapeutic development and risk assessment

artículo científico publicado en 2012

Nivo-lution in Mesothelioma

artículo científico publicado en 2019

Novel Germline Mutations in DNA Damage Repair in Patients with Malignant Pleural Mesotheliomas

scientific article published on 28 December 2019

Novel and Targeted Therapies

Novel therapies in phase II and III trials for malignant pleural mesothelioma.

artículo científico publicado en 2012

Patterns of toxicity in older patients with breast cancer receiving adjuvant chemotherapy

artículo científico publicado en 2005

Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors

artículo científico publicado en 2016

Phase II Study of Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) As Part of Lung-Sparing Multimodality Therapy in Patients With Malignant Pleural Mesothelioma

artículo científico publicado en 2016

Pleural intensity-modulated radiotherapy for malignant pleural mesothelioma

artículo científico publicado en 2012

Pleurectomy/decortication, chemotherapy, and intensity modulated radiation therapy for malignant pleural mesothelioma: rationale for multimodality therapy incorporating lung-sparing surgery

artículo científico publicado en 2012

Practical Application of Real-World Evidence in Developing Cancer Therapies

artículo científico publicado en 2019

Prevalence and Preliminary Validation of Screening Criteria to Identify Carriers of Germline BAP1 Mutations

artículo científico publicado en 2019

Serum Biomarkers Associated with Clinical Outcomes Fail to Predict Brain Metastases in Patients with Stage IV Non-Small Cell Lung Cancers

artículo científico publicado en 2016

The evolution of multimodality therapy for malignant pleural mesothelioma

artículo científico publicado en 2011

Toxicity of initial chemotherapy in older patients with lung cancers

artículo científico publicado en 2013

Trial of a 5-day dosing regimen of temozolomide in patients with relapsed small cell lung cancers with assessment of methylguanine-DNA methyltransferase

artículo científico publicado en 2014

V-domain Ig-containing suppressor of T-cell activation (VISTA), a potentially targetable immune checkpoint molecule, is highly expressed in epithelioid malignant pleural mesothelioma

scientific article published on 19 September 2019

Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma.

artículo científico publicado en 2014

Workshop summary: potential usefulness and feasibility of a US national mesothelioma registry

artículo científico publicado en 2019

Lista de obras de Marjorie Zauderer

"A Tool, Not a Crutch": Patient Perspectives About IBM Watson for Oncology Trained by Memorial Sloan Kettering

A Randomized Phase II Trial of Adjuvant Galinpepimut-S, WT-1 Analogue Peptide Vaccine, After Multimodality Therapy for Patients with Malignant Pleural Mesothelioma

A new standard for malignant pleural mesothelioma

A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma

A prospective study of tumor suppressor gene methylation as a prognostic biomarker in surgically resected stage I to IIIA non-small-cell lung cancers.

COVID-19 in patients with lung cancer

Cancer antigen profiling for malignant pleural mesothelioma immunotherapy: expression and coexpression of mesothelin, cancer antigen 125, and Wilms tumor 1.

Change in cycle 1 to cycle 2 haematological counts predicts toxicity in older patients with breast cancer receiving adjuvant chemotherapy

Chemotherapy-induced immunomodulation in non-small-cell lung cancer: a rationale for combination chemoimmunotherapy

Clinical characteristics of patients with malignant pleural mesothelioma harboring somatic BAP1 mutations.

Combined Inhibition of NEDD8-Activating Enzyme and mTOR Suppresses NF2 Loss-Driven Tumorigenesis.

Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization

Contemporary Analysis of Prognostic Factors in Patients with Unresectable Malignant Pleural Mesothelioma

Creating a Synthetic Clinical Trial: Comparative Effectiveness Analyses Using an Electronic Medical Record

Current and Future Management of Malignant Mesothelioma : A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer and Mesothelioma Applied Research Foundatio

Developing a cancer-specific geriatric assessment

Failure patterns after hemithoracic pleural intensity modulated radiation therapy for malignant pleural mesothelioma

Feasibility and toxicity of dose-dense adjuvant chemotherapy in older women with breast cancer

Globular C1q Receptor (gC1qR/p32/HABP1) Is Overexpressed in Malignant Pleural Mesothelioma and Is Associated With Increased Survival in Surgical Patients Treated With Chemotherapy

Heart Dosimetry is Correlated With Risk of Radiation Pneumonitis After Lung-Sparing Hemithoracic Pleural Intensity Modulated Radiation Therapy for Malignant Pleural Mesothelioma

Hemithoracic radiotherapy for mesothelioma: lack of benefit or lack of statistical power?

Important recent insights into the genetics and biology of malignant pleural mesothelioma

Improved Outcomes with Modern Lung-Sparing Trimodality Therapy in Patients with Malignant Pleural Mesothelioma.

Inherited Rare, Deleterious Variants in ATM Increase Lung Adenocarcinoma Risk

Integrative Molecular Characterization of Malignant Pleural Mesothelioma

Leptomeningeal metastases from small cell lung cancer responsive to temozolomide therapy

Localized malignant pleural mesothelioma with renal metastasis

Loss of BAP1 as a candidate predictive biomarker for immunotherapy of mesothelioma

Malignant Pleural Mesothelioma: Are There Imaging Characteristics Associated With Different Histologic Subtypes on Computed Tomography?

Mesothelioma: Scientific clues for prevention, diagnosis, and therapy

New strategies in pleural mesothelioma: BAP1 and NF2 as novel targets for therapeutic development and risk assessment

Nivo-lution in Mesothelioma

Novel Germline Mutations in DNA Damage Repair in Patients with Malignant Pleural Mesotheliomas

Novel and Targeted Therapies

Novel therapies in phase II and III trials for malignant pleural mesothelioma.

Patterns of toxicity in older patients with breast cancer receiving adjuvant chemotherapy

Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors

Phase II Study of Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) As Part of Lung-Sparing Multimodality Therapy in Patients With Malignant Pleural Mesothelioma

Pleural intensity-modulated radiotherapy for malignant pleural mesothelioma

Pleurectomy/decortication, chemotherapy, and intensity modulated radiation therapy for malignant pleural mesothelioma: rationale for multimodality therapy incorporating lung-sparing surgery

Practical Application of Real-World Evidence in Developing Cancer Therapies

Prevalence and Preliminary Validation of Screening Criteria to Identify Carriers of Germline BAP1 Mutations

Serum Biomarkers Associated with Clinical Outcomes Fail to Predict Brain Metastases in Patients with Stage IV Non-Small Cell Lung Cancers

The evolution of multimodality therapy for malignant pleural mesothelioma

Toxicity of initial chemotherapy in older patients with lung cancers

Trial of a 5-day dosing regimen of temozolomide in patients with relapsed small cell lung cancers with assessment of methylguanine-DNA methyltransferase

V-domain Ig-containing suppressor of T-cell activation (VISTA), a potentially targetable immune checkpoint molecule, is highly expressed in epithelioid malignant pleural mesothelioma

Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma.

Workshop summary: potential usefulness and feasibility of a US national mesothelioma registry